Business
CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference
PRINCETON, N.J., Feb. 27, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the
About this update from Cytosorbents Corporation
[{"type":"text","content":"PRINCETON, N.J., Feb. 27, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the Cowen 43rd Annual Health Care Conference at the Boston Marriott Copley Place, in Boston, MA on Tuesday, March 7, 2023. Company management will also meet in-person with investors in 1x1 meetings during the conference. To schedule a meeting with management, please contact your Cowen representative.\n\n \n \n \n \n \n \n\n \nCowen Annual Health Care Conference \nWhen: Tuesday, March 7, 2023 from 1:30PM-2:00PM ESTWhere: Boston Marriott Copley Place, Arlington Room (3rd floor)Webcast: Cowen Presentation Webcast Link \nAbout CytoSorbents Corporation (NASDAQ: CTSO) \nCytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its lead product, CytoSorb®, is approved in the European Union and distributed in 75 countries worldwide. It is an extracorporeal cytokine adsorber that reduces \"cytokine storm\" or \"cytokine release syndrome\" in common critical illnesses that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, including severe bleeding and multiple organ failure. At the end of 2022, more than 195,000 CytoSorb devices have been used cumulatively. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. The DrugSorb™-ATR antithrombotic removal system, based on the same polymer technology as CytoSorb, also re...